知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

338 条记录 (耗时 0.054 秒)

    Optical information reproducing apparatus and optical information reproducing method
    1.
    发明授权
    Optical information reproducing apparatus and optical information reproducing method 有权
    光信息再现装置和光信息再现方法

    公开(公告)号：US08947991B2

    公开(公告)日：2015-02-03

    申请号：US14118080

    申请日：2012-04-19

    申请人： Yusuke Nakamura ,  Hajime Ishihara

    发明人： Yusuke Nakamura ,  Hajime Ishihara

    IPC分类号： G11B7/00 ,  G11B7/007 ,  G11B20/18 ,  G11B20/10

    CPC分类号： G11B7/00772 ,  G11B20/10055 ,  G11B20/1012 ,  G11B20/10287 ,  G11B20/10379 ,  G11B20/18 ,  G11B2020/185 ,  G11B2220/2504

    摘要： A method of calculating a reliability effective in a decoding process of hologram. An optical information reproducing apparatus that reproduces information with the use of the holography includes an image acquisition unit that reproduces two-dimensional data from a hologram disc, an image equalization unit that makes the two-dimensional data equal to target data having a target PR characteristic, a soft output decoding unit that decodes output data of the image equalization unit on the basis of the PR characteristic, and outputs a decoded result having a reliability, and an error correction unit that conducts an error correction of the data on the basis of the decoded result.

    摘要翻译： 一种在全息图解码过程中计算可靠性有效的方法。 利用全息图再现信息的光学信息再现装置包括从全息光盘再现二维数据的图像获取单元，使得二维数据等于具有目标PR特性的目标数据的图像均衡单元 ，软输出解码单元，其基于PR特性对图像均衡单元的输出数据进行解码，并输出具有可靠性的解码结果;以及纠错单元，其基于所述PR特性进行数据的错误校正 解码结果。

    INFORMATION REPRODUCTION APPARATUS AND INFORMATION REPRODUCTION METHOD
    2.
    发明申请
    INFORMATION REPRODUCTION APPARATUS AND INFORMATION REPRODUCTION METHOD 审中-公开
    信息再现装置和信息再现方法

    公开(公告)号：US20130083873A1

    公开(公告)日：2013-04-04

    申请号：US13550640

    申请日：2012-07-17

    申请人： Hajime ISHIHARA ,  Yusuke Nakamura ,  Yutaka Nagai

    发明人： Hajime ISHIHARA ,  Yusuke Nakamura ,  Yutaka Nagai

    IPC分类号： H04L27/06

    CPC分类号： G11B20/10296 ,  G11B20/10055 ,  H03M13/4107 ,  H03M13/6561

    摘要： An information reproduction apparatus includes a generator of a channel clock synchronized to input data, an analog/digital converter for converting the input data with an 1/N clock which is in frequency one Nth (N: a positive real number) of the channel clock, and a Viterbi decoder including a unit for calculating a branch metric based on a difference between an output of the converter and a reference value, an ACS unit responsive to input of data corresponding to one time point of the 1/N clock, for adding the branch metric for one time point to an old path metric, comparing addition results, selecting a smaller result, and outputting a new path metric and a path selection signal, according to state transitions with N bits as a unit, a unit for determining a maximum likelihood path based on the selection signal, and a decoder for outputting a decoding result.

    摘要翻译： 信息再现装置包括与输入数据同步的通道时钟的发生器，用于以1 / N时钟转换输入数据的模拟/数字转换器，该时钟频率为通道时钟频率的第N（N：正实数） 以及维特比解码器，其包括用于基于转换器的输出与参考值之间的差来计算分支量度的单元，响应于对应于1 / N时钟的一个时间点的数据的输入的ACS单元，用于添加 一个时间点到旧路径度量的分支度量，根据N位作为一个单元的状态转换，比较加法结果，选择较小的结果，并输出新的路径量度和路径选择信号， 基于选择信号的最大似然路径，以及用于输出解码结果的解码器。

    SEMA5B peptides and vaccines including the same
    3.
    发明授权
    SEMA5B peptides and vaccines including the same 有权
    SEMA5B肽和疫苗包括它们

    公开(公告)号：US09187556B2

    公开(公告)日：2015-11-17

    申请号：US14118693

    申请日：2012-06-07

    申请人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    发明人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    IPC分类号： C07K14/00 ,  C07K16/18 ,  C07K14/47 ,  G01N33/574 ,  A61K39/00 ,  A61K38/00

    CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/4703 ,  G01N33/57492 ,  G01N2333/70539

    摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.

    摘要翻译： 如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。

    ECT2 peptides and vaccines including the same
    6.
    发明授权
    ECT2 peptides and vaccines including the same 有权
    ECT2肽和疫苗包括它们

    公开(公告)号：US08951975B2

    公开(公告)日：2015-02-10

    申请号：US13638272

    申请日：2011-03-30

    申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： A61K38/08 ,  A61K38/10 ,  A61K38/00 ,  A61K38/04 ,  C07K7/06 ,  A61K39/00

    CPC分类号： C07K7/06 ,  A61K39/0011 ,  A61K2039/572

    摘要： Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.

    摘要翻译： 衍生自SEQ ID NO：42的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保留所需的HLA结合和/或CTL诱导性 的原始序列。 还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。 本发明的肽，核酸，药物，物质和组合物在治疗癌症和肿瘤方面特别有用，包​​括例如膀胱癌，乳腺癌，子宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌 ，NSCLC，淋巴瘤，胰腺癌，前列腺癌，肾癌和SCLC。

    Method of diagnosing esophageal cancer
    8.
    发明授权
    Method of diagnosing esophageal cancer 有权
    诊断食管癌的方法

    公开(公告)号：US08771963B2

    公开(公告)日：2014-07-08

    申请号：US13246639

    申请日：2011-09-27

    申请人： Yusuke Nakamura ,  Yataro Daigo ,  Shuichi Nakatsuru

    发明人： Yusuke Nakamura ,  Yataro Daigo ,  Shuichi Nakatsuru

    IPC分类号： C12Q1/00 ,  G01N1/00 ,  G01N33/53 ,  G01N33/566 ,  G01N33/567 ,  G01N33/574

    CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y10T436/25

    摘要： In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer.

    摘要翻译： 为了鉴定涉及食管癌发生的分子以及可用于诊断标志物以及新药和免疫治疗靶标的分子，构建了代表32,256个基因的cDNA微阵列，分析19例食管鳞状细胞癌（ESCCS）的表达谱 ）通过激光捕获显微切割纯化。 本文公开了在食管癌中显着上调或下调的基因组的详细全基因组数据库。 这些基因可用于治疗药物或免疫治疗以及肿瘤标志物的开发。 此外，本文公开了与淋巴结转移和手术后复发相关的基因。 在候选分子靶基因中，进一步表征ECT2，CDC45L和DKK1。 用ECT2或CDC45L的小干扰RNA（siRNA）处理ESCC细胞抑制癌细胞的生长。 因此，本文的数据提供了用于鉴定诊断系统和用于食管癌的治疗靶分子的有价值的信息。

    SEMA5B PEPTIDES AND VACCINES INCLUDING THE SAME
    9.
    发明申请
    SEMA5B PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    SEMA5B肽和疫苗，包括它们

    公开(公告)号：US20140178409A1

    公开(公告)日：2014-06-26

    申请号：US14118693

    申请日：2012-06-07

    申请人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    发明人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    IPC分类号： C07K16/18

    CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/4703 ,  G01N33/57492 ,  G01N2333/70539

    摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.

    摘要翻译： 如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。